science
Gilead and Merck Say HIV Pill Combination Hits Primary Goal in Phase 3 Trials
The companies reported that their long-acting combination pill reached its main efficacy target in late-stage testing.
cnbc.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Gilead and Merck said an experimental long acting pill combining two HIV medicines had met its primary efficacy goal in final-stage trials. The statement from the two companies confirmed that the pill reached the main efficacy target set for the late-stage study. An experimental long acting pill combines two HIV medicines, according to the trial description released with the announcement.
@business reported the companies' joint announcement on the trial outcome.
Transparency
1 source · single source
CorroborationLimited · 1 source
